286 related articles for article (PubMed ID: 30948493)
21. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
22. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma.
Song IS; Jeong YJ; Jeong SH; Kim HK; Ha NC; Shin M; Ko KS; Rhee BD; Shim S; Jang SW; Han J
Cancer Lett; 2018 Sep; 432():205-215. PubMed ID: 29933047
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
25. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
26. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
[TBL] [Abstract][Full Text] [Related]
28. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
29. Molecular determinants of NF-kappaB-inducing kinase action.
Lin X; Mu Y; Cunningham ET; Marcu KB; Geleziunas R; Greene WC
Mol Cell Biol; 1998 Oct; 18(10):5899-907. PubMed ID: 9742107
[TBL] [Abstract][Full Text] [Related]
30. Targeting aurora kinases as therapy in multiple myeloma.
Shi Y; Reiman T; Li W; Maxwell CA; Sen S; Pilarski L; Daniels TR; Penichet ML; Feldman R; Lichtenstein A
Blood; 2007 May; 109(9):3915-21. PubMed ID: 17213289
[TBL] [Abstract][Full Text] [Related]
31. TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.
Kanno Y; Sakurai D; Hase H; Kojima H; Kobata T
J Recept Signal Transduct Res; 2010 Apr; 30(2):121-32. PubMed ID: 20184394
[TBL] [Abstract][Full Text] [Related]
32. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
33. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.
Yamamoto M; Ito T; Shimizu T; Ishida T; Semba K; Watanabe S; Yamaguchi N; Inoue J
Cancer Sci; 2010 Nov; 101(11):2391-7. PubMed ID: 20735436
[TBL] [Abstract][Full Text] [Related]
35. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
Ma J; Gong W; Liu S; Li Q; Guo M; Wang J; Wang S; Chen N; Wang Y; Liu Q; Zhao H
Tumour Biol; 2018 Jan; 40(1):1010428317731369. PubMed ID: 29320977
[TBL] [Abstract][Full Text] [Related]
37. NFκB-inducing kinase inhibits NFκB activity specifically in neurons of the CNS.
Mao X; Phanavanh B; Hamdan H; Moerman-Herzog AM; Barger SW
J Neurochem; 2016 Apr; 137(2):154-63. PubMed ID: 26778773
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
39. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.
Demchenko YN; Glebov OK; Zingone A; Keats JJ; Bergsagel PL; Kuehl WM
Blood; 2010 Apr; 115(17):3541-52. PubMed ID: 20053756
[TBL] [Abstract][Full Text] [Related]
40. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.
Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M
Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
